First-in-Human, Phase 1 Study of PHN-012, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors
Pheon Therapeutics
Summary
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Has histologically confirmed, advanced/metastatic: 1. Colorectal adenocarcinoma (CRC), or 2. Non-small cell lung cancer (NSCLC), or 3. Pancreatic ductal adenocarcinoma (PDAC). * Has received at least one prior systemic therapy and radiologically or clinically determined progressive disease during or after the most recent line of therapy, and for whom no further standard therapy is available or who is intolerant to standard therapy. * Has measurable disease. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Has adequate organ function. * H…
Interventions
- DrugPHN-012
PHN-012 is an ADC
Locations (21)
- PHN-012-001 SiteLos Angeles, California
- PHN-012-001 SiteSan Diego, California
- PHN-012-001 SiteWashington D.C., District of Columbia
- PHN-012-001 SiteBoston, Massachusetts
- PHN-012-001 SiteSt Louis, Missouri
- PHN-012-001 SiteDurham, North Carolina